Overview

Study to ONO-4538 in Patients With Rhabdoid Tumor

Status:
RECRUITING
Trial end date:
2030-03-31
Target enrollment:
Participant gender:
Summary
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Phase:
PHASE2
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Nivolumab